Fred R. Hirsch

Colorado, New York

I am Executive Director at the Center for Thoracic Oncology at Mount Sinai Hospital , NYC and Professor of Medicine at Icahn Medical School at Mount Sinai, NY

Featured in: Favicon

fortune.com Favicon

mdpi.com

tandfonline.com Favicon

jamanetwork.com Favicon

thelancet.com Favicon

healio.com Favicon

ascopost.com Favicon

onclive.com Favicon

curetoday.com Favicon

targetedonc.com + 4 more

Articles

Dr Hirsch on the Benefits of Tissue vs Liquid Biopsy in NSCLC

Aug 12, 2024 | onclive.com | Fred R. Hirsch

CommentaryVideoAugust 12, 2024Author(s): Fred R. Hirsch, MD, PhD, discusses the pros and cons of completing a tissue biopsy compared with a liquid biopsy in non–small cell lung cancer. Fred R.
Choosing the Optimal NSCLC Treatment

Jul 31, 2024 | cancernetwork.com | Fred R. Hirsch |Mary Beasley |Nicole Hall |Philip C. Mack |Daniel G Nicastri |Nicholas Rohs | +1 more

A group of experts discuss the current treatment algorithm for NSCLC, as well as novel approaches under investigation, the impact of molecular biomarkers on their treatment decisions, and the importance of clinical trials.
Choosing the Optimal NSCLC Treatment

Jul 31, 2024 | cancernetwork.com | Fred R. Hirsch |Mary Beasley |Nicole Hall |Philip C. Mack |Daniel G Nicastri |Nicholas Rohs | +1 more

A group of experts discuss the current treatment algorithm for NSCLC, as well as novel approaches under investigation, the impact of molecular biomarkers on their treatment decisions, and the importance of clinical trials.
Important NSCLC Biomarkers

Jul 31, 2024 | cancernetwork.com | Fred R. Hirsch |Mary Beasley |Nicole Hall |Philip C. Mack |Daniel G Nicastri |Nicholas Rohs | +1 more

Fred R. Hirsch, MD, PhD, leads a discussion with his Mount Sinai colleagues about important biomarkers found in non-small cell lung cancer, including those that provide predictive and prognostic information.
Important NSCLC Biomarkers

Jul 31, 2024 | cancernetwork.com | Fred R. Hirsch |Mary Beasley |Nicole Hall |Philip C. Mack |Daniel G Nicastri |Nicholas Rohs | +1 more

Fred R. Hirsch, MD, PhD, leads a discussion with his Mount Sinai colleagues about important biomarkers found in non-small cell lung cancer, including those that provide predictive and prognostic information.
Providing Supportive Care to Patients with NSCLC

Jul 31, 2024 | cancernetwork.com | Fred R. Hirsch |Mary Beasley |Nicole Hall |Philip C. Mack |Daniel G Nicastri |Nicholas Rohs | +1 more

Helping patients manage potential treatment-related adverse events is an essential part of the overall care plan in the treatment of non-small cell lung cancer. Experts provide strategies to address adverse events and best practices for providing the supportive care needed for patients.
Providing Supportive Care to Patients with NSCLC

Jul 31, 2024 | cancernetwork.com | Fred R. Hirsch |Mary Beasley |Nicole Hall |Philip C. Mack |Daniel G Nicastri |Nicholas Rohs | +1 more

Helping patients manage potential treatment-related adverse events is an essential part of the overall care plan in the treatment of non-small cell lung cancer. Experts provide strategies to address adverse events and best practices for providing the supportive care needed for patients.
Biomarker Testing Best Practices in NSCLC

Jul 31, 2024 | cancernetwork.com | Fred R. Hirsch |Mary Beasley |Nicole Hall |Philip C. Mack |Daniel G Nicastri |Nicholas Rohs | +1 more

Non-small cell lung cancer experts share biomarker testing protocols and best practices for optimal outcomes, with a focus on overcoming challenges and nuances of testing.
Biomarker Testing Best Practices in NSCLC

Jul 31, 2024 | cancernetwork.com | Fred R. Hirsch |Mary Beasley |Nicole Hall |Philip C. Mack |Daniel G Nicastri |Nicholas Rohs | +1 more

Non-small cell lung cancer experts share biomarker testing protocols and best practices for optimal outcomes, with a focus on overcoming challenges and nuances of testing.
Dr Hirsch on the Treatment of NRG1 Fusion+ NSCLC

Jul 25, 2024 | onclive.com | Fred R. Hirsch

CommentaryVideoJuly 25, 2024Author(s):Fact checked by:Fred R. Hirsch, MD, PhD, discusses the activity of HER3-directed agents in patients with non–small cell lung cancer harboring NRG1 mutations. Fred R.